Tumor Biology

, Volume 35, Issue 10, pp 9905–9910 | Cite as

The expression of Survivin and NF-κB associated with prognostically worse clinicopathologic variables in hepatocellular carcinoma

  • Yi Jin
  • Jianning Chen
  • Zhiying Feng
  • Wenzhe Fan
  • Yu Wang
  • Jiaping LiEmail author
  • Dayue TongEmail author
Research Article


Expressions of Survivin and nuclear factor of kappa light polypeptide gene enhancer in B cells (NF-κB) are associated with a poor prognosis in many malignancies. However, their relationship in hepatocellular carcinoma remains unclear. To investigate the protein expression of Survivin and NF-κB, determine their role in the pathogenesis of hepatocellular carcinoma, and correlate expression with patient survival outcome, immunohistochemistry was used to detect the protein expression of Survivin and NF-κB in 305 cases of hepatocellular carcinoma. Statistical analysis was performed to determine the relationship between the protein expression of Survivin and NF-κB and clinicopathological parameters, survival time, and prognosis. Survivin was expressed predominantly in the cytoplasm, and NF-κB was expressed mostly in the nucleolus. Survivin and NF-κB are expressed at significantly higher rates in hepatocellular carcinoma compared with benign tissue (75.7 vs 13.4 %, P < 0.01 and 79.0 vs 17.1 %, P < 0.01, respectively). Both Survivin and NF-κB expression levels are associated with poor prognostic factors, including tumor size, capsular invasion, tumor thrombus of the portal vein, metastasis of the lymph node, and clinical staging. There was an obvious positive correlation between the expression of Survivin and NF-κB in hepatocellular carcinoma (r = 0.23, P < 0.01). Patients expressing Survivin and NF-κB had significantly shorter survival compared with patients negative for protein expression (P < 0.01). The overexpressions of both Survivin and NF-κB are associated with worse survival outcome in patients with hepatocellular carcinoma. Thus, these proteins could be used as negative prognostic indicators.


Hepatocellular carcinoma Immunohistochemistry Survivin NF-κB 



This work was supported by the National Natural Science Foundation of China (no. 81171441, 81301694, 81371653), the Science and Technology Program of Guangdong Province (no. 2012B060300009, 2011B031800146), the Natural Science Foundation of Guangdong Province (no. S2012020010904, 7001663, S2011010004247), and the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (no.20111139).

Conflicts of interest



  1. 1.
    Flores A, Marrero JA. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol. 2014;8:71–6.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, et al. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol. 2014;20:5935–50.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 2013;1:593–8.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Kim HY, Park JW. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer. 2014;3:9–17.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Li W, Tan D, Zenali MJ, Brown RE. Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol. 2009;3:238–43.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Huang JL, Zheng L, Hu YW, Wang Q. Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. Carcinogenesis. 2014;35:507–14.CrossRefPubMedGoogle Scholar
  7. 7.
    Cho S, Lee JH, Cho SB, Yoon KW, Park SY, Lee WS, et al. Epigenetic methylation and expression of caspase 8 and survivin in hepatocellular carcinoma. Pathol Int. 2010;60(3):203–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Goossens-Beumer IJ, Zeestraten EC, Benard A, Christen T, Reimers MS, Keijzer R, et al. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. Br J Cancer. 2014;110:2935–44.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Pickhard A, Gröber S, Haug AK, Piontek G, Wirth M, Straßen U, et al. Survivin and pAkt as potential prognostic markers in squamous cell carcinoma of the head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117:733–42.CrossRefPubMedGoogle Scholar
  10. 10.
    Gu Y, Jin S, Wang F, Hua Y, Yang L, Shu Y, et al. Clinicopathological significance of PI3K, Akt and survivin expression in gastric cancer. Biomed Pharmacother. 2014;68:471–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Altieri DC. Targeting survivin in cancer. Cancer Lett. 2013;332:225–8.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Song J, Su H, Zhou YY, Guo LL. Prognostic value of survivin expression in breast cancer patients: a meta-analysis. Tumour Biol. 2013;34:2053–62.CrossRefPubMedGoogle Scholar
  13. 13.
    Liu JL, Gao W, Kang QM, Zhang XJ, Yang SG. Prognostic value of survivin in patients with gastric cancer: a systematic review with meta-analysis. PLoS One. 2013;8:e71930.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 2013;12:86.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    He G, Karin M. NF-κB and STAT3—key players in liver inflammation and cancer. Cell Res. 2011;21:159–68.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Wan F, Lenardo MJ. The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives. Cell Res. 2010;20:24–33.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Vaiopoulos AG, Athanasoula KC, Papavassiliou AG. NF-κB in colorectal cancer. J Mol Med (Berlin). 2013;91:1029–37.CrossRefGoogle Scholar
  18. 18.
    Nair VS, Gevaert O, Davidzon G, Plevritis SK, West R. NF-κB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism. Lung Cancer. 2014;83:189–96.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Zhang M, Zhang X, Zhao S, Wang Y, Di W, Zhao G, et al. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients. Target Oncol. 2013 Nov 15. [Epub ahead of print]Google Scholar
  20. 20.
    Cheng CW, Chow AK, Pang R, Fok EW, Kwong YL, Tse E. PIN1 inhibits apoptosis in hepatocellular carcinoma through modulation of the antiapoptotic function of survivin. Am J Pathol. 2013;182:765–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, et al. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol. 2008;33:287–95.PubMedGoogle Scholar
  22. 22.
    Wu W, Yao DF, Qiu LW, Sai WL, Shen JJ, Yu HB, et al. Characteristics of hepatic nuclear-transcription factor-kappa B expression and quantitative analysis in rat hepatocarcinogenesis. Hepatobiliary Pancreat Dis Int. 2009;8:504–9.PubMedGoogle Scholar
  23. 23.
    He Y, Zhang H, Yin J, Xie J, Tan X, Liu S, et al. IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. Carcinogenesis. 2009;30:1916–22.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Omar HA, Sargeant AM, Weng JR, Wang D, Kulp SK, Patel T, et al. Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Mol Pharmacol. 2009;76:957–68.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Pathology, The Third Affiliated HospitalSun Yat-Sen UniversityGuangzhouChina
  2. 2.Department of Interventional Oncology, The First Affiliated HospitalSun Yat-Sen UniversityGuangzhouChina
  3. 3.Department of Forensic Medicine, ZhongShan Medical SchoolSun Yat-Sen UniversityGuangzhouChina

Personalised recommendations